CLEC1B (C-type lectin domain family 1 member B), also known as CLEC-2, is a platelet-expressed C-type lectin receptor with multifaceted roles in hemostasis and immunity. CLEC1B functions as a transmembrane signaling receptor that binds podoplanin and other ligands to promote platelet activation and aggregation 1. The receptor mediates leukocyte-platelet aggregate formation and supports thrombus formation at inflammatory sites in mouse models 23. Additionally, CLEC1B acts as an attachment factor facilitating HIV-1 capture by platelets [UniProt reference]. CLEC1B expression is regulated by genetic variants; haplotype h3 homozygosity correlates with significantly lower soluble CLEC-2 plasma levels in healthy individuals 4. Dysregulated CLEC1B expression associates with disease pathogenesis. In hepatocellular carcinoma, reduced CLEC1B expression combined with elevated PD-L1 predicts poor prognosis and worse tumor progression 5. Reduced CLEC1B is induced by endocrine-disrupting chemicals (PFOA/PFOS) through estrogen receptor interference, promoting lipid metabolic dysregulation in HCC 6. CLEC1B associates with Parkinson's disease risk and progression as identified through integrative genetic-proteomic analysis 7. These findings establish CLEC1B as both a critical regulator of platelet-mediated inflammation and a potential biomarker and therapeutic target in multiple diseases.